Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fulcrum Therapeutics, Inc. (FULC)
USD3.55
-0.04 (-1.25%)
US NASDAQ Healthcare Biotechnology
Address
26 Landsdowne Street 2139
Cambridge, MA, US
Cambridge, MA, US
CEO
Alexander C. Sapir
Website
fulcrumtx.com
IPO
2019-07-18
CIK 1680581 ISIN US3596161097
Description
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.55
-0.04 (-1.25%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
2.92
Float Shares
48.00M
Free Float %
88.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.47% | +5.17% | -2.95% | -17.42% | -36.75% | -38.82% | +0.58% | +139.45% | -20.82% | -48.74% | -48.74% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (16 ratings, all time)
Buy
Price Targets & DCF
Current price
3.55
Low
10.00
+182.1%
Consensus
20.67
+483.0%
Median
23.50
+562.8%
High
25.00
+605.2%
DCF (Unlevered)
3.01
-15.1%
DCF (Levered)
3.02
-14.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 12 |
18.50
+421.8%
|
| All Time | 26 |
14.77
+316.6%
|
Quality scores
Altman Z-Score
14.20
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-637.5% Q1'26: +10.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-2,387.0% Q1'26: -1,516.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.2% ★ Q1'26: +22.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 10 EPS Ana. |
Dec 2027 9 Rev. Ana. 9 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.82M
est: 5.69M (+55.1%)
|
19.16M
est: 14.39M (+33.2%)
|
6.34M
est: 7.35M (-13.7%)
|
2.81M
est: 81.63M (-96.6%)
|
80.00M
est: 80.47M (-0.6%)
|
—
est: 28.06M (-100.0%)
|
311.9K
311.9K – 311.9K
-98.9% YoY
|
361.24M
361.24M – 361.24M
+115,722.9% YoY
|
51.68M
51.68M – 51.68M
-85.7% YoY
|
130.73M
130.73M – 130.73M
+153.0% YoY
|
222.74M
222.74M – 222.74M
+70.4% YoY
|
| EBITDA |
-69.23M
est: -4.81M (-1,339.5%)
|
-78.54M
est: -12.16M (-545.6%)
|
-109.72M
est: -6.21M (-1,666.2%)
|
-108.49M
est: -36.37M (-198.3%)
|
-18.24M
est: -35.86M (+49.1%)
|
-73.49M
est: -12.50M (-487.8%)
|
-139.0K
-139.0K – -139.0K
+98.9% YoY
|
-160.97M
-160.97M – -160.97M
-115,723.7% YoY
|
-23.03M
-23.03M – -23.03M
+85.7% YoY
|
-58.25M
-58.25M – -58.25M
-153.0% YoY
|
-99.25M
-99.25M – -99.25M
-70.4% YoY
|
| EBIT |
-71.61M
est: -4.83M (-1,381.9%)
|
-81.05M
est: -12.22M (-563.2%)
|
-112.13M
est: -6.24M (-1,696.6%)
|
-110.66M
est: -36.70M (-201.5%)
|
-19.83M
est: -36.18M (+45.2%)
|
-74.88M
est: -12.61M (-493.6%)
|
-140.2K
-140.2K – -140.2K
+98.9% YoY
|
-162.41M
-162.41M – -162.41M
-115,722.9% YoY
|
-23.23M
-23.23M – -23.23M
+85.7% YoY
|
-58.77M
-58.77M – -58.77M
-153.0% YoY
|
-100.14M
-100.14M – -100.14M
-70.4% YoY
|
| Net Income |
-70.82M
est: -173.35M (+59.1%)
|
-80.85M
est: -152.81M (+47.1%)
|
-109.87M
est: -149.63M (+26.6%)
|
-97.34M
est: -20.68M (-370.6%)
|
-9.73M
est: -9.10M (-6.8%)
|
-74.88M
est: -76.12M (+1.6%)
|
-87.23M
-88.78M – -65.32M
-14.6% YoY
|
-102.94M
-108.54M – -58.79M
-18.0% YoY
|
-76.42M
-126.09M – 28.26M
+25.8% YoY
|
-6.97M
-6.97M – -6.97M
+90.9% YoY
|
50.53M
50.53M – 50.53M
+825.0% YoY
|
| SGA |
21.39M
est: 29.46M (-27.4%)
|
30.52M
est: 74.52M (-59.1%)
|
41.69M
est: 38.06M (+9.6%)
|
41.67M
est: 399.61M (-89.6%)
|
36.45M
est: 393.95M (-90.7%)
|
28.67M
est: 137.35M (-79.1%)
|
1.53M
1.53M – 1.53M
-98.9% YoY
|
1.77B
1.77B – 1.77B
+115,722.9% YoY
|
252.99M
252.99M – 252.99M
-85.7% YoY
|
639.98M
639.98M – 639.98M
+153.0% YoY
|
1.09B
1.09B – 1.09B
+70.4% YoY
|
| EPS |
-2.70
est: -2.80 (+3.5%)
|
-2.22
est: -2.47 (+9.9%)
|
-2.35
est: -2.41 (+2.7%)
|
-1.59
est: -0.33 (-387.0%)
|
-0.16
est: -0.15 (-7.9%)
|
-1.18
est: -1.16 (-1.4%)
|
-1.16
-1.40 – -1.03
+0.2% YoY
|
-1.32
-1.71 – -0.93
-13.3% YoY
|
-1.02
-1.99 – 0.45
+22.4% YoY
|
-0.11
-0.11 – -0.11
+89.2% YoY
|
0.80
0.80 – 0.80
+825.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-165.22M
OE per share TTM
-2.59
Owner's Yield
-31.33%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
127.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
174
Total invested
550.14M
Insider transactions (90d)
1
Beneficial owners (>5%)
36
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peter Kolchinsky | 7.00M | 13.45% | — | 7.00M | — | — | HC, IN | United States of America | 2022-08-26 | ↗ |
| 2 | RA Capital Healthcare Fund, L.P. | 7.00M | 13.45% | — | 7.00M | — | — | PN | Delaware | 2022-08-26 | ↗ |
| 3 | RA Capital Management, L.P. | 7.00M | 13.45% | — | 7.00M | — | — | IA, PN | Delaware | 2022-08-26 | ↗ |
| 4 | Rajeev Shah | 7.00M | 13.45% | — | 7.00M | — | — | HC, IN | United States of America | 2022-08-26 | ↗ |
| 5 | (1) BlackRock, Inc. | 5.58M | 10.30% | 5.42M | — | 5.58M | — | HC | Delaware | 2024-12-06 | ↗ |
| 6 | Chen Yu | 5.00M | 9.40% | — | 5.00M | — | 5.00M | IN | Delaware | 2024-09-20 | ↗ |
| 7 | TCG Crossover Fund II, L.P. | 5.00M | 9.40% | — | 5.00M | — | 5.00M | PN | Delaware | 2024-09-20 | ↗ |
| 8 | TCG Crossover GP II, LLC | 5.00M | 9.40% | — | 5.00M | — | 5.00M | OO | Delaware | 2024-09-20 | ↗ |
| 9 | Mark Levin | 4.05M | 10.00% | 84.2K | 3.96M | 84.2K | 3.96M | IN | — | 2022-02-14 | ↗ |
| 10 | Robert I. Tepper | 4.05M | 10.00% | 84.2K | 3.96M | 84.2K | 3.96M | IN | — | 2022-02-14 | ↗ |
| 11 | Kevin P. Starr | 4.05M | 10.00% | 84.2K | 3.96M | 84.2K | 3.96M | IN | — | 2022-02-14 | ↗ |
| 12 | TRV GP III, LLC | 3.96M | 9.80% | — | 3.96M | — | 3.96M | OO | — | 2022-02-14 | ↗ |
| 13 | Third Rock Ventures GP III, L.P. | 3.96M | 9.80% | — | 3.96M | — | 3.96M | PN | — | 2022-02-14 | ↗ |
| 14 | Third Rock Ventures III, L.P. | 3.96M | 9.80% | — | 3.96M | — | 3.96M | PN | — | 2022-02-14 | ↗ |
| 15 | Adage Capital Advisors, L.L.C. | 3.47M | 5.63% | — | 3.47M | — | — | OO | Delaware | 2023-03-06 | ↗ |
| 16 | Adage Capital Partners GP, L.L.C. | 3.47M | 5.63% | — | 3.47M | — | — | OO | Delaware | 2023-03-06 | ↗ |
| 17 | Adage Capital Partners, L.P. | 3.47M | 5.63% | — | 3.47M | — | — | PN | Delaware | 2023-03-06 | ↗ |
| 18 | Phillip Gross | 3.47M | 5.63% | — | 3.47M | — | — | IN | United States | 2023-03-06 | ↗ |
| 19 | Robert Atchinson | 3.47M | 5.63% | — | 3.47M | — | — | IN | United States | 2023-03-06 | ↗ |
| 20 | Aaron Cowen | 2.38M | 5.90% | — | 2.38M | — | 2.38M | HC, IN | — | 2022-02-11 | ↗ |
| 21 | Averill Master Fund, Ltd. | 2.38M | 5.90% | — | 2.38M | — | 2.38M | CO | — | 2022-02-11 | ↗ |
| 22 | Suvretta Capital Management, LLC | 2.38M | 5.90% | — | 2.38M | — | 2.38M | IA, OO | — | 2022-02-11 | ↗ |
| 23 | TRV GP IV, LLC | 2.34M | 5.80% | — | 2.34M | — | 2.34M | OO | — | 2022-02-14 | ↗ |
| 24 | Third Rock Ventures GP IV, L.P. | 2.34M | 5.80% | — | 2.34M | — | 2.34M | PN | — | 2022-02-14 | ↗ |
| 25 | Third Rock Ventures IV, L.P. | 2.34M | 5.80% | — | 2.34M | — | 2.34M | PN | — | 2022-02-14 | ↗ |
| 26 | RTW Investments, LP | 2.07M | 7.54% | — | 2.07M | — | 2.07M | IA, PN, OO | OR PLACE OF ORGANIZATION | 2021-02-12 | ↗ |
| 27 | Roderick Wong | 2.07M | 7.54% | — | 2.07M | — | 2.07M | HC, IN | OR PLACE OF ORGANIZATION | 2021-02-12 | ↗ |
| 28 | Steven A. Cohen | 2.07M | 4.00% | — | 2.07M | — | 2.07M | IN | Citizenship or place of organization United States | 2022-06-22 | ↗ |
| 29 | GlaxoSmithKline plc | 1.79M | 4.50% | 1.79M | — | 1.79M | 1.79M | CO | England and Wales | 2021-09-27 | ↗ |
| 30 | Point72 Asset Management, L.P. | 1.75M | 4.00% | — | 1.75M | — | 1.75M | PN | Citizenship or place of organization Delaware | 2022-06-22 | ↗ |
| 31 | Point72 Capital Advisors, Inc. | 1.75M | 4.00% | — | 1.75M | — | 1.75M | CO | Citizenship or place of organization Delaware | 2022-06-22 | ↗ |
| 32 | Abigail P. Johnson | 1.72M | 2.76% | — | — | 1.72M | — | IN | Delaware | 2024-10-07 | ↗ |
| 33 | FMR LLC | 1.72M | 2.76% | 1.72M | — | 1.72M | — | HC | Delaware | 2024-10-07 | ↗ |
| 34 | RTW Master Fund, Ltd. | 1.44M | 5.24% | — | 1.44M | — | 1.44M | CO | OR PLACE OF ORGANIZATION | 2021-02-12 | ↗ |
| 35 | Cubist Systematic Strategies, LLC | 313.6K | 4.00% | — | 313.6K | — | 313.6K | OO | Citizenship or place of organization Delaware | 2022-06-22 | ↗ |
| 36 | Point72 Hong Kong Limited | 4.3K | 4.00% | — | 4.3K | — | 4.3K | OO | Citizenship or place of organization Hong Kong | 2022-06-22 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
174
-4 vs prev Q
New positions
36
Closed positions
40
Increased
109
Reduced
39
Put/Call ratio
0.25
Calls held
571.0K
Puts held
142.2K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 50.0K +50.0K (+100.0%) | 565.50M +565.5M (+100.0%) | 0.08% +0.080 pp | 0.55% +0.547 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 2 | SUVRETTA CAPITAL MANAGEMENT, LLC | 6.56M +1.2M (+21.9%) | 74.21M +24.7M (+49.9%) | 10.48% +1.878 pp | 1.52% +0.253 pp | USD6.54 +72.9% | 20 qtrs — |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 6.05M -4.2M (-40.8%) | 68.47M -25.6M (-27.2%) | 9.67% -6.684 pp | 0.70% -0.458 pp | USD6.97 +62.3% | 14 qtrs — |
| 4 | TCG CROSSOVER MANAGEMENT, LLC | 5.25M +— (+0.0%) | 59.38M +11.1M (+22.9%) | 8.39% -0.007 pp | 1.97% -0.411 pp | USD3.57 +216.8% | 6 qtrs — |
| 5 | NANTAHALA CAPITAL MANAGEMENT, LLC | 4.29M -377.4K (-8.1%) | 48.56M +5.6M (+13.0%) | 6.86% -0.609 pp | 1.61% +0.113 pp | USD4.03 +180.6% | 6 qtrs — |
| 6 | BLACKROCK, INC. | 4.26M +557.0K (+15.0%) | 48.22M +14.1M (+41.4%) | 6.81% +0.885 pp | 0.00% +0.000 pp | USD4.58 +146.9% | 6 qtrs — |
| 7 | VANGUARD GROUP INC | 3.56M +560.1K (+18.7%) | 40.26M +12.7M (+45.9%) | 5.69% +0.891 pp | 0.00% +0.000 pp | USD10.38 +9.0% | 26 qtrs — |
| 8 | BRAIDWELL LP | 3.06M +2.8M (+1,294.7%) | 34.62M +32.6M (+1,614.6%) | 4.89% +4.539 pp | 1.11% +1.047 pp | USD11.16 +1.3% | 2 qtrs — |
| 9 | POINT72 ASSET MANAGEMENT, L.P. | 2.40M +2.4M (+100.0%) | 27.12M +27.1M (+100.0%) | 3.83% +3.831 pp | 0.03% +0.030 pp | USD11.31 +0.0% | 3 qtrs — |
| 10 | SIREN, L.L.C. | 1.95M +2.0M (+100.0%) | 22.05M +22.1M (+100.0%) | 3.12% +3.115 pp | 0.66% +0.658 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 11 | D. E. SHAW & CO., INC. | 1.91M +464.3K (+32.0%) | 21.64M +8.3M (+62.3%) | 3.06% +0.740 pp | 0.01% +0.004 pp | USD7.98 +41.7% | 18 qtrs — |
| 12 | FIRST TURN MANAGEMENT, LLC | 1.89M +1.9M (+100.0%) | 21.41M +21.4M (+100.0%) | 3.02% +3.024 pp | 2.45% +2.446 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 13 | GSK PLC | 1.79M +1.8M (+100.0%) | 20.20M +20.2M (+100.0%) | 2.85% +2.853 pp | 2.53% +2.528 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 14 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.70M -732.0K (-30.1%) | 19.23M -3.1M (-14.1%) | 2.72% -1.173 pp | 0.03% -0.006 pp | USD5.19 +117.9% | 18 qtrs — |
| 15 | IKARIAN CAPITAL, LLC | 1.38M +86.2K (+6.7%) | 15.56M +3.7M (+31.2%) | 2.20% +0.136 pp | 1.21% +0.017 pp | USD8.23 +37.4% | 6 qtrs — |
| 16 | ABRDN PLC | 1.25M +1.1M (+809.0%) | 14.18M +12.9M (+1,017.4%) | 2.00% +1.783 pp | 0.02% +0.020 pp | USD10.97 +3.1% | 3 qtrs — |
| 17 | ADAR1 CAPITAL MANAGEMENT, LLC | 1.25M +912.1K (+267.0%) | 14.18M +11.0M (+351.2%) | 2.00% +1.457 pp | 1.04% +0.746 pp | USD10.51 +7.6% | 9 qtrs — |
| 18 | CITADEL ADVISORS LLC | 1.21M +352.4K (+41.2%) | 13.65M +5.8M (+73.6%) | 1.93% +0.562 pp | 0.00% +0.001 pp | USD9.18 +23.2% | 19 qtrs — |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 1.11M +101.8K (+10.1%) | 12.51M +3.3M (+35.4%) | 1.77% +0.161 pp | 0.00% +0.000 pp | USD8.37 +35.1% | 26 qtrs — |
| 20 | DIMENSIONAL FUND ADVISORS LP | 1.05M -248.2K (-19.1%) | 11.89M -62.4K (-0.5%) | 1.68% -0.398 pp | 0.00% 0.000 pp | USD7.43 +52.2% | 20 qtrs — |
| 21 | STATE STREET CORP | 1.01M -57.9K (-5.4%) | 11.37M +1.6M (+16.2%) | 1.61% -0.094 pp | 0.00% +0.000 pp | USD6.15 +83.9% | 25 qtrs — |
| 22 | BALYASNY ASSET MANAGEMENT L.P. | 970.4K -480.0K (-33.1%) | 10.98M -2.4M (-17.8%) | 1.55% -0.769 pp | 0.01% -0.003 pp | USD7.06 +60.2% | 3 qtrs — |
| 23 | VESTAL POINT CAPITAL, LP | 950.0K +950.0K (+100.0%) | 10.74M +10.7M (+100.0%) | 1.52% +1.518 pp | 0.37% +0.365 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 24 | GREAT POINT PARTNERS LLC | 800.0K +800.0K (+100.0%) | 9.05M +9.0M (+100.0%) | 1.28% +1.278 pp | 2.93% +2.934 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 25 | ACADIAN ASSET MANAGEMENT LLC | 736.7K +196.1K (+36.3%) | 8.33M +3.4M (+67.5%) | 1.18% +0.313 pp | 0.01% +0.005 pp | USD6.30 +79.5% | 6 qtrs — |
| 26 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 582.4K +198.2K (+51.6%) | 6.59M +3.1M (+86.4%) | 0.93% +0.316 pp | 0.02% +0.006 pp | USD7.59 +49.0% | 6 qtrs — |
| 27 | NORTHERN TRUST CORP | 552.2K -16.1K (-2.8%) | 6.25M +1.0M (+19.5%) | 0.88% -0.027 pp | 0.00% +0.000 pp | USD5.19 +117.9% | 26 qtrs — |
| 28 | BOOTHBAY FUND MANAGEMENT, LLC | 517.5K -160.9K (-23.7%) | 5.85M -388.2K (-6.2%) | 0.83% -0.258 pp | 0.09% -0.003 pp | USD8.49 +33.2% | 6 qtrs — |
| 29 | JANE STREET GROUP, LLC | 493.8K +172.2K (+53.6%) | 5.58M +2.6M (+88.8%) | 0.79% +0.275 pp | 0.00% +0.000 pp | USD9.77 +15.8% | 18 qtrs — |
| 30 | INVESCO LTD. | 417.2K +293.3K (+236.8%) | 4.72M +3.6M (+314.0%) | 0.67% +0.468 pp | 0.00% +0.001 pp | USD9.85 +14.8% | 9 qtrs — |
| 31 | SILVERARC CAPITAL MANAGEMENT, LLC | 394.7K +394.7K (+100.0%) | 4.46M +4.5M (+100.0%) | 0.63% +0.631 pp | 0.62% +0.620 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 32 | QUBE RESEARCH & TECHNOLOGIES LTD | 392.5K +392.5K (+100.0%) | 4.44M +4.4M (+100.0%) | 0.63% +0.627 pp | 0.00% +0.005 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 33 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 388.9K +55.4K (+16.6%) | 4.40M +1.3M (+43.4%) | 0.62% +0.088 pp | 0.00% +0.000 pp | USD5.58 +102.7% | 24 qtrs — |
| 34 | SIO CAPITAL MANAGEMENT, LLC | 382.0K +382.0K (+100.0%) | 4.32M +4.3M (+100.0%) | 0.61% +0.610 pp | 0.68% +0.680 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 35 | TREXQUANT INVESTMENT LP | 355.5K +334.5K (+1,591.9%) | 4.02M +3.8M (+1,979.9%) | 0.57% +0.534 pp | 0.04% +0.034 pp | USD11.19 +1.1% | 2 qtrs — |
| 36 | GOLDMAN SACHS GROUP INC | 323.9K -262.5K (-44.8%) | 3.66M -1.7M (-32.1%) | 0.52% -0.420 pp | 0.00% 0.000 pp | USD6.86 +64.9% | 21 qtrs — |
| 37 | DEUTSCHE BANK AG\ | 287.1K +1.8K (+0.6%) | 3.25M +622.0K (+23.7%) | 0.46% +0.002 pp | 0.00% +0.000 pp | USD6.82 +65.8% | 9 qtrs — |
| 38 | BESSEMER GROUP INC | 287.0K +— (+0.0%) | 3.25M +604.0K (+22.9%) | 0.46% 0.000 pp | 0.01% +0.001 pp | USD8.36 +35.3% | 26 qtrs — |
| 39 | DRIEHAUS CAPITAL MANAGEMENT LLC | 243.4K +243.4K (+100.0%) | 2.75M +2.8M (+100.0%) | 0.39% +0.389 pp | 0.02% +0.019 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 40 | BANK OF AMERICA CORP /DE/ | 231.2K +84.0K (+57.0%) | 2.61M +1.3M (+93.1%) | 0.37% +0.134 pp | 0.00% +0.000 pp | USD9.07 +24.7% | 26 qtrs — |
| 41 | CATALIO CAPITAL MANAGEMENT, LP | 201.3K +201.3K (+100.0%) | 2.28M +2.3M (+100.0%) | 0.32% +0.322 pp | 0.40% +0.402 pp | USD11.31 +0.0% | 4 qtrs — |
| 42 | NICHOLAS INVESTMENT PARTNERS, LP | 183.0K +183.0K (+100.0%) | 2.07M +2.1M (+100.0%) | 0.29% +0.292 pp | 0.15% +0.151 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 43 | WELLS FARGO & COMPANY/MN | 166.4K +133.9K (+411.9%) | 1.88M +1.6M (+529.3%) | 0.27% +0.214 pp | 0.00% +0.000 pp | USD10.27 +10.1% | 26 qtrs — |
| 44 | MORGAN STANLEY | 165.6K -78.2K (-32.1%) | 1.87M -370.1K (-16.5%) | 0.26% -0.125 pp | 0.00% +0.000 pp | USD7.49 +51.0% | 26 qtrs — |
| 45 | SIMPLIFY ASSET MANAGEMENT INC. | 159.7K +76.4K (+91.8%) | 1.81M +1.0M (+135.8%) | 0.26% +0.122 pp | 0.03% +0.015 pp | USD7.81 +44.8% | 12 qtrs — |
| 46 | AMERICAN CENTURY COMPANIES INC | 157.7K +5.4K (+3.6%) | 1.78M +382.6K (+27.3%) | 0.25% +0.009 pp | 0.00% +0.000 pp | USD6.48 +74.5% | 12 qtrs — |
| 47 | WELLINGTON MANAGEMENT GROUP LLP | 146.4K -32.9K (-18.4%) | 1.66M +6.0K (+0.4%) | 0.23% -0.053 pp | 0.00% +0.000 pp | USD7.56 +49.6% | 8 qtrs — |
| 48 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 140.5K +74.0K (+111.3%) | 1.59M +977.3K (+159.7%) | 0.22% +0.118 pp | 0.00% +0.000 pp | USD9.00 +25.7% | 18 qtrs — |
| 49 | SUMMITTX CAPITAL, L.P. | 138.1K +138.1K (+100.0%) | 1.56M +1.6M (+100.0%) | 0.22% +0.221 pp | 0.05% +0.047 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 50 | FIDUCIARY TRUST CO | 136.6K +— (+0.0%) | 1.54M +288.1K (+22.9%) | 0.22% 0.000 pp | 0.02% +0.003 pp | USD12.27 -7.8% | 26 qtrs — |
| 51 | BARCLAYS PLC | 132.5K +8.4K (+6.8%) | 1.50M +1.1M (+238.2%) | 0.21% +0.013 pp | 0.00% +0.000 pp | USD5.75 +96.7% | 16 qtrs — |
| 52 | BANK OF NEW YORK MELLON CORP | 116.9K -2.3K (-1.9%) | 1.32M +226.0K (+20.6%) | 0.19% -0.004 pp | 0.00% +0.000 pp | USD6.23 +81.5% | 24 qtrs — |
| 53 | NUVEEN, LLC | 112.2K +— (+0.0%) | 1.27M +236.7K (+22.9%) | 0.18% 0.000 pp | 0.00% +0.000 pp | USD2.88 +292.7% | 4 qtrs — |
| 54 | WALLEYE CAPITAL LLC | 108.4K +108.4K (+100.0%) | 1.23M +1.2M (+100.0%) | 0.17% +0.173 pp | 0.00% +0.004 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 55 | UBS GROUP AG | 103.0K -198.2K (-65.8%) | 1.16M -1.6M (-58.0%) | 0.16% -0.317 pp | 0.00% 0.000 pp | USD8.15 +38.8% | 13 qtrs — |
| 56 | MARSHALL WACE, LLP | 102.9K +102.9K (+100.0%) | 1.16M +1.2M (+100.0%) | 0.16% +0.164 pp | 0.00% +0.001 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 57 | AMERIPRISE FINANCIAL INC | 100.7K -24.0K (-19.2%) | 1.14M -8.3K (-0.7%) | 0.16% -0.039 pp | 0.00% +0.000 pp | USD9.20 +22.9% | 2 qtrs — |
| 58 | MAVEN SECURITIES LTD | 100.0K +100.0K (+100.0%) | 1.13M +1.1M (+100.0%) | 0.16% +0.160 pp | 0.03% +0.025 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 59 | GSA CAPITAL PARTNERS LLP | 99.7K -16.4K (-14.1%) | 1.13M +60.0K (+5.6%) | 0.16% -0.026 pp | 0.10% +0.008 pp | USD8.55 +32.3% | 3 qtrs — |
| 60 | PRINCIPAL FINANCIAL GROUP INC | 97.7K +31.1K (+46.8%) | 1.10M +492.6K (+80.5%) | 0.16% +0.050 pp | 0.00% +0.000 pp | USD9.87 +14.6% | 2 qtrs — |
| 61 | JUMP FINANCIAL, LLC | 92.2K +92.2K (+100.0%) | 1.04M +1.0M (+100.0%) | 0.15% +0.147 pp | 0.01% +0.013 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 62 | EXOME ASSET MANAGEMENT LLC | 92.1K -6.7K (-6.8%) | 1.04M +132.2K (+14.5%) | 0.15% -0.011 pp | 0.50% -0.053 pp | USD3.63 +211.6% | 7 qtrs — |
| 63 | STATE OF WISCONSIN INVESTMENT BOARD | 86.5K +72.8K (+533.0%) | 978.3K +852.6K (+678.1%) | 0.14% +0.116 pp | 0.00% +0.002 pp | USD10.98 +3.0% | 2 qtrs — |
| 64 | RBF CAPITAL, LLC | 80.5K +— (+0.0%) | 910.5K +169.9K (+22.9%) | 0.13% 0.000 pp | 0.04% +0.007 pp | USD3.30 +242.7% | 11 qtrs — |
| 65 | VERITION FUND MANAGEMENT LLC | 74.7K +74.7K (+100.0%) | 844.8K +844.8K (+100.0%) | 0.12% +0.119 pp | 0.00% +0.003 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 66 | SUPERSTRING CAPITAL MANAGEMENT LP | 72.1K +72.1K (+100.0%) | 815.0K +815.0K (+100.0%) | 0.12% +0.115 pp | 0.44% +0.436 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 67 | CITIGROUP INC | 67.1K +66.4K (+9,245.7%) | 758.9K +752.3K (+11,390.1%) | 0.11% +0.106 pp | 0.00% +0.000 pp | USD11.24 +0.6% | 26 qtrs — |
| 68 | Y-INTERCEPT (HONG KONG) LTD | 66.7K +55.4K (+491.9%) | 754.6K +650.9K (+627.6%) | 0.11% +0.089 pp | 0.02% +0.014 pp | USD10.95 +3.3% | 12 qtrs — |
| 69 | LEGATO CAPITAL MANAGEMENT LLC | 66.3K +66.3K (+100.0%) | 750.4K +750.4K (+100.0%) | 0.11% +0.106 pp | 0.06% +0.065 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 70 | SQUAREPOINT OPS LLC | 65.9K +48.0K (+269.4%) | 744.8K +580.8K (+354.1%) | 0.11% +0.077 pp | 0.00% +0.001 pp | USD10.26 +10.2% | 3 qtrs — |
| 71 | PRICE T ROWE ASSOCIATES INC /MD/ | 63.8K -2.1K (-3.2%) | 722.0K +115.0K (+18.9%) | 0.10% -0.004 pp | 0.00% +0.000 pp | USD5.81 +94.7% | 18 qtrs — |
| 72 | INTEGRATED QUANTITATIVE INVESTMENTS LLC | 62.5K +62.5K (+100.0%) | 707.1K +707.1K (+100.0%) | 0.10% +0.100 pp | 0.15% +0.152 pp | USD11.31 +0.0% | 3 qtrs — |
| 73 | EAM INVESTORS, LLC | 61.6K +61.6K (+100.0%) | 696.9K +696.9K (+100.0%) | 0.10% +0.098 pp | 0.08% +0.078 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 74 | ATOM INVESTORS LP | 60.6K +60.6K (+100.0%) | 685.3K +685.3K (+100.0%) | 0.10% +0.097 pp | 0.05% +0.054 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 75 | NEW YORK STATE COMMON RETIREMENT FUND | 57.7K +44.6K (+340.6%) | 652.9K +532.4K (+441.7%) | 0.09% +0.071 pp | 0.00% +0.001 pp | USD10.18 +11.1% | 7 qtrs — |
| 76 | RHUMBLINE ADVISERS | 55.7K -13.7K (-19.7%) | 630.1K -8.1K (-1.3%) | 0.09% -0.022 pp | 0.00% +0.000 pp | USD6.35 +78.1% | 23 qtrs — |
| 77 | DEKABANK DEUTSCHE GIROZENTRALE | 60.0K +— (+0.0%) | 617.0K +6.0K (+1.0%) | 0.10% 0.000 pp | 0.00% +0.000 pp | USD4.44 +154.7% | 10 qtrs — |
| 78 | MILLENNIUM MANAGEMENT LLC | 54.4K -96.4K (-63.9%) | 615.6K -772.4K (-55.6%) | 0.09% -0.154 pp | 0.00% 0.000 pp | USD7.14 +58.4% | 12 qtrs — |
| 79 | XTX TOPCO LTD | 51.8K +51.8K (+100.0%) | 585.9K +585.9K (+100.0%) | 0.08% +0.083 pp | 0.02% +0.015 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 80 | SEVEN GRAND MANAGERS, LLC | 50.0K +50.0K (+100.0%) | 565.5K +565.5K (+100.0%) | 0.08% +0.080 pp | 0.04% +0.043 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 81 | BURKEHILL GLOBAL MANAGEMENT, LP | 50.0K +50.0K (+100.0%) | 565.5K +565.5K (+100.0%) | 0.08% +0.080 pp | 0.04% +0.037 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 82 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 48.9K +33.6K (+219.5%) | 559.4K +418.6K (+297.3%) | 0.08% +0.054 pp | 0.01% +0.006 pp | USD10.65 +6.2% | 2 qtrs — |
| 83 | STRS OHIO | 49.3K -28.6K (-36.7%) | 557.6K -159.1K (-22.2%) | 0.08% -0.046 pp | 0.00% -0.001 pp | USD3.77 +200.0% | 6 qtrs — |
| 84 | GRAHAM CAPITAL MANAGEMENT, L.P. | 48.5K +18.0K (+59.0%) | 548.1K +267.7K (+95.4%) | 0.08% +0.029 pp | 0.01% +0.009 pp | USD8.65 +30.8% | 6 qtrs — |
| 85 | FRANKLIN RESOURCES INC | 44.2K -15.8K (-26.3%) | 500.5K -51.7K (-9.4%) | 0.07% -0.025 pp | 0.00% +0.000 pp | USD5.40 +109.4% | 11 qtrs — |
| 86 | HSBC HOLDINGS PLC | 43.3K -10.5K (-19.6%) | 497.9K +23.9K (+5.0%) | 0.07% -0.017 pp | 0.00% +0.000 pp | USD4.39 +157.6% | 8 qtrs — |
| 87 | JAIN GLOBAL LLC | 41.3K +41.3K (+100.0%) | 466.7K +466.7K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.002 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 88 | COMMONWEALTH EQUITY SERVICES, LLC | 40.0K -43.4K (-52.1%) | 452.4K -315.6K (-41.1%) | 0.06% -0.070 pp | 0.00% 0.000 pp | USD9.27 +22.0% | 8 qtrs — |
| 89 | SEI INVESTMENTS CO | 37.5K +37.5K (+100.0%) | 424.2K +424.2K (+100.0%) | 0.06% +0.060 pp | 0.00% +0.000 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 90 | CAMPBELL & CO INVESTMENT ADVISER LLC | 35.6K -66.9K (-65.3%) | 402.6K -540.1K (-57.3%) | 0.06% -0.107 pp | 0.02% -0.052 pp | USD9.20 +22.9% | 2 qtrs — |
| 91 | GROUP ONE TRADING, L.P. | 34.8K +29.0K (+503.3%) | 393.0K +340.0K (+641.7%) | 0.06% +0.046 pp | 0.00% +0.001 pp | USD10.42 +8.5% | 10 qtrs — |
| 92 | AXQ CAPITAL, LP | 31.5K +31.5K (+100.0%) | 356.8K +356.8K (+100.0%) | 0.05% +0.050 pp | 0.08% +0.081 pp | USD11.31 +0.0% | 1 qtrs NEW |
| 93 | WOODLINE PARTNERS LP | 30.8K +30.8K (+100.0%) | 348.3K +348.3K (+100.0%) | 0.05% +0.049 pp | 0.00% +0.001 pp | USD11.31 +0.0% | 7 qtrs — |
| 94 | TWO SIGMA ADVISERS, LP | 30.5K -1.0K (-3.2%) | 345.0K +55.2K (+19.0%) | 0.05% -0.002 pp | 0.00% +0.000 pp | USD4.93 +129.4% | 18 qtrs — |
| 95 | COUNTRY TRUST BANK | 30.0K +— (+0.0%) | 339.8K +63.4K (+22.9%) | 0.05% +0.000 pp | 0.01% +0.000 pp | USD11.85 -4.6% | 24 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 73 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 0.64% | 3.03M | 0.35% |
| 2 | Simplify Health Care ETF PINK | 0.15% | 567.7K | 0.51% |
| 3 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.13% | 31.1K | 1.22% |
| 4 | ALPS Medical Breakthroughs ETF SBIO | 0.12% | 254.7K | 0.50% |
| 5 | Vanguard U.S. Momentum Factor ETF VFMO | 0.08% | 1.36M | 0.13% |
| 6 | Vanguard Global Momentum Factor ETF VMO.TO | 0.06% | 210.4K | 0.38% |
| 7 | iShares Micro-Cap ETF IWC | 0.05% | 698.1K | 0.60% |
| 8 | Vanguard Russell 2000 Value ETF VTWV | 0.02% | 312.0K | 0.06% |
| 9 | Fidelity Enhanced Small Cap ETF FESM | 0.02% | 1.16M | 0.28% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.02% | 12.1K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.33
Neutral
Ratio by volume
3.00
Bullish
Buys
4
Sells
3
Shares acquired
1.05M
Shares disposed
45.0K
Cash buys
—
Cash sales
3.00
Net activity
+1,002,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Lehrer-Graiwer Joshua | Director | A-Award | A | Stock Option (right to buy) | 64,000 | 8.08 | 517.1K | 64,000 | D | ↗ |
| 2026-02-02 | Tourangeau Greg | Officer | A-Award | A | Stock Option (right to buy) | 57,000 | 10.72 | 611.0K | 57,000 | D | ↗ |
| 2026-02-02 | Sapir Alex | Director / Officer | A-Award | A | Stock option - Right to Buy | 650,000 | 10.72 | 6.97M | 650,000 | D | ↗ |
| 2026-02-02 | Oltmans Curtis Gale | Officer | A-Award | A | Stock Option (right to buy) | 170,000 | 10.72 | 1.82M | 170,000 | D | ↗ |
| 2026-02-02 | Musso Alan A | Officer | A-Award | A | Stock Option (right to buy) | 170,000 | 10.72 | 1.82M | 170,000 | D | ↗ |
| 2026-02-02 | Gould Robert J | Director | S-Sale | D | Common Stock | 15,000 | 10.72 | 160.9K | 454,864 | D | ↗ |
| 2026-01-02 | Gould Robert J | Director | S-Sale | D | Common Stock | 15,000 | 11.87 | 178.1K | 469,864 | D | ↗ |
| 2025-12-15 | Oltmans Curtis Gale | Officer | S-Sale | D | Common Stock | 3,452 | 12.92 | 44.6K | 10,252 | D | ↗ |
| 2025-12-08 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,377,020 | 13.33 | 18.36M | 8,852,079 | I | ↗ |
| 2025-11-19 | Gould Robert J | Director | S-Sale | D | Common Stock | 15,000 | 11.03 | 165.5K | 484,864 | D | ↗ |
| 2025-06-26 | King Rachel K. | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 7.38 | 265.7K | 36,000 | D | ↗ |
| 2025-06-26 | Hill Colin | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 7.38 | 265.7K | 36,000 | D | ↗ |
| 2025-06-26 | Haviland Kate | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 7.38 | 265.7K | 36,000 | D | ↗ |
| 2025-06-26 | Gould Robert J | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 7.38 | 265.7K | 36,000 | D | ↗ |
| 2025-06-26 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 7.38 | 265.7K | 36,000 | D | ↗ |
| 2025-06-26 | Ezekowitz Alan | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 7.38 | 265.7K | 36,000 | D | ↗ |
| 2025-06-26 | Dorton Katina | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 7.38 | 265.7K | 36,000 | D | ↗ |
| 2025-06-26 | Banks Sonja | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 7.38 | 265.7K | 36,000 | D | ↗ |
| 2025-05-08 | Tourangeau Greg | Officer | S-Sale | D | Common Stock | 498 | 5.06 | 2.5K | 14,062 | D | ↗ |
| 2025-01-24 | Tourangeau Greg | Officer | A-Award | A | Stock Option (right to buy) | 76,120 | 4.16 | 316.7K | 76,120 | D | ↗ |
| 2025-01-24 | Sapir Alex | Director / Officer | A-Award | A | Stock option - Right to Buy | 582,000 | 4.16 | 2.42M | 582,000 | D | ↗ |
| 2025-01-24 | Oltmans Curtis Gale | Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 4.16 | 936.0K | 225,000 | D | ↗ |
| 2025-01-24 | Musso Alan A | Officer | A-Award | A | Stock Option (right to buy) | 285,000 | 4.16 | 1.19M | 285,000 | D | ↗ |
| 2024-11-12 | King Rachel K. | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 3.64 | 218.4K | 60,000 | D | ↗ |
| 2024-09-12 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 10,229,099 | I | ↗ |
| 2024-08-21 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | J-Other | A | Warrant (Right to Buy) | 8,500,000 | 0.00 | 8.5K | 8,500,000 | — | ↗ |
| 2024-07-03 | Sapir Alex | Director / Officer | M-Exempt | D | Stock option - Right to Buy | 150,000 | 3.27 | 490.5K | 2,280,400 | — | ↗ |
| 2024-06-17 | Hill Colin | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-17 | Haviland Kate | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 7.00 | 210.0K | 30,000 | — | ↗ |
| 2024-06-17 | Gould Robert J | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 7.00 | 210.0K | 30,000 | — | ↗ |
| 2024-06-17 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 7.00 | 210.0K | 30,000 | — | ↗ |
| 2024-06-17 | Ezekowitz Alan | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 7.00 | 210.0K | 30,000 | — | ↗ |
| 2024-06-17 | Dorton Katina | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 7.00 | 210.0K | 30,000 | — | ↗ |
| 2024-06-17 | Collins James J. | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 7.00 | 210.0K | 30,000 | — | ↗ |
| 2024-06-17 | Banks Sonja | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 7.00 | 210.0K | 30,000 | — | ↗ |
| 2024-05-07 | Tourangeau Greg | Officer | S-Sale | D | Common Stock | 236 | 7.76 | 1.8K | 11,571 | — | ↗ |
| 2024-03-18 | Horn Patrick Taylor | Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 10.12 | 4.05M | 400,000 | — | ↗ |
| 2024-03-08 | Tourangeau Greg | Officer | S-Sale | D | Common Stock | 4,884 | 11.72 | 57.2K | 11,807 | — | ↗ |
| 2024-03-04 | Sapir Alex | Director / Officer | P-Purchase | A | Common Stock | 43,360 | 11.35 | 492.0K | 43,360 | — | ↗ |
| 2024-01-26 | Tourangeau Greg | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 6.95 | 69.5K | 10,000 | — | ↗ |
| 2024-01-26 | Oltmans Curtis Gale | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 6.95 | 1.04M | 150,000 | — | ↗ |
| 2024-01-26 | Musso Alan A | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 6.95 | 695.0K | 100,000 | — | ↗ |
| 2024-01-17 | Musso Alan A | Officer | A-Award | A | Stock Option (right to buy) | 61,822 | 4.01 | 247.9K | 61,822 | — | ↗ |
| 2023-08-07 | Musso Alan A | Officer | A-Award | A | Stock Option (right to buy) | 432,800 | 4.01 | 1.74M | 432,800 | — | ↗ |
| 2023-07-01 | Sapir Alex | Director / Officer | — | D | Stock Option (right to buy) | 2,430,400 | 3.27 | 7.95M | 0 | — | ↗ |
| 2023-06-27 | Haviland Kate | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 3.16 | 94.8K | 30,000 | — | ↗ |
| 2023-06-27 | Gould Robert J | Director / Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 3.16 | 94.8K | 30,000 | — | ↗ |
| 2023-06-27 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 3.16 | 94.8K | 30,000 | — | ↗ |
| 2023-06-27 | Ezekowitz Alan | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 3.16 | 94.8K | 30,000 | — | ↗ |
| 2023-06-27 | Dorton Katina | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.16 | 94.8K | 30,000 | — | ↗ |
| 2023-06-27 | Collins James J. | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 3.16 | 94.8K | 30,000 | — | ↗ |
| 2023-06-27 | Banks Sonja | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 3.16 | 94.8K | 30,000 | — | ↗ |
| 2023-05-10 | Tourangeau Greg | Officer | S-Sale | D | Common Stock | 210 | 3.31 | 695.10 | 15,992 | — | ↗ |
| 2023-04-26 | Oltmans Curtis Gale | Officer | A-Award | A | Stock Option (right to buy) | 127,500 | 2.58 | 329.0K | 127,500 | — | ↗ |
| 2023-04-26 | Hayes Melvin H. III | Officer | A-Award | A | Stock Option (right to buy) | 115,000 | 2.58 | 296.7K | 115,000 | — | ↗ |
| 2023-02-09 | Tourangeau Greg | Officer | A-Award | A | Stock Option (right to buy) | 16,100 | 12.59 | 202.7K | 16,100 | — | ↗ |
| 2023-02-09 | Rajavelu Esther | Officer | A-Award | A | Stock Option (right to buy) | 160,000 | 12.59 | 2.01M | 160,000 | — | ↗ |
| 2023-02-09 | Oltmans Curtis Gale | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 12.59 | 1.89M | 150,000 | — | ↗ |
| 2023-02-09 | Hayes Melvin H. III | Officer | A-Award | A | Stock Option (right to buy) | 135,000 | 12.59 | 1.70M | 135,000 | — | ↗ |
| 2023-01-20 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 1,923,076 | 13.00 | 25.00M | 11,609,704 | — | ↗ |
| 2023-01-13 | Gould Robert J | Officer | S-Sale | D | Common Stock | 6,766 | 15.00 | 101.5K | 499,864 | — | ↗ |
| 2023-01-04 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 58,369 | 7.80 | 455.1K | 9,686,628 | — | ↗ |
| 2022-12-27 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 4,089 | 5.99 | 24.5K | 9,505,925 | — | ↗ |
| 2022-12-19 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 98,787 | 5.90 | 582.8K | 9,501,836 | — | ↗ |
| 2022-12-16 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 1,341,420 | 5.42 | 7.27M | 9,403,049 | — | ↗ |
| 2022-12-15 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 237,029 | 5.50 | 1.30M | 8,061,629 | — | ↗ |
| 2022-12-14 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 824,600 | 5.46 | 4.50M | 7,824,600 | — | ↗ |
| 2022-12-13 | Third Rock Ventures III, L.P. | Director | J-Other | D | Common Stock | 2,000,000 | 0.00 | — | 1,962,202 | — | ↗ |
| 2022-11-07 | Arroyo Santiago | Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 0.00 | — | 400,000 | — | ↗ |
| 2022-08-16 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 7,000,000 | — | ↗ |
| 2022-08-09 | Oltmans Curtis Gale | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 7.40 | 370.0K | 50,000 | — | ↗ |
| 2022-08-09 | Hayes Melvin H. III | Officer | — | D | Stock Option (right to buy) | 140,000 | 28.49 | 3.99M | 0 | — | ↗ |
| 2022-07-15 | Tourangeau Greg | Officer | A-Award | A | Stock Option (right to buy) | 16,540 | 0.00 | — | 16,540 | — | ↗ |
| 2022-06-27 | Haviland Kate | Director | A-Award | A | Stock Option (right to buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-06-27 | Gould Robert J | Director | A-Award | A | Stock Option (right to buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-06-27 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (right to buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-06-27 | Ezekowitz Alan | Director | J-Other | D | Stock Option (right to buy) | 500 | 0.00 | — | 14,500 | — | ↗ |
| 2022-06-27 | Dorton Katina | Director | A-Award | A | Stock Option (right to buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-06-27 | Collins James J. | Director | A-Award | A | Stock Option (right to buy) | 19,000 | 5.22 | 99.2K | 19,000 | — | ↗ |
| 2022-06-27 | Banks Sonja | Director | A-Award | A | Stock Option (right to buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2022-06-07 | Gould Robert J | Director | S-Sale | D | Common Stock | 71,435 | 8.09 | 577.9K | 506,630 | — | ↗ |
| 2022-06-02 | Gould Robert J | Director | S-Sale | D | Common Stock | 16,689 | 7.92 | 132.2K | 506,630 | — | ↗ |
| 2022-05-06 | Tourangeau Greg | Officer | A-Award | A | Stock Option (right to buy) | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2022-04-07 | Gould Robert J | Director | S-Sale | D | Common Stock | 5,631 | 24.02 | 135.2K | 506,630 | — | ↗ |
| 2022-04-01 | Gould Robert J | Director | M-Exempt | A | Common Stock | 34,464 | 7.84 | 270.2K | 541,094 | — | ↗ |
| 2022-03-11 | Tourangeau Greg | Officer | — | D | Stock Option (right to buy) | 9,868 | 12.46 | 123.0K | 0 | — | ↗ |
| 2022-01-19 | Thomson Peter G. | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 12.69 | 507.6K | 40,000 | — | ↗ |
| 2022-01-19 | Stuart Bryan | Director / Officer | A-Award | A | Stock Option (right to buy) | 340,000 | 12.69 | 4.31M | 340,000 | — | ↗ |
| 2022-01-19 | Oltmans Curtis Gale | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 12.69 | 761.4K | 60,000 | — | ↗ |
| 2022-01-19 | Morabito Christopher | Officer | A-Award | A | Stock Option (right to buy) | 59,744 | 12.69 | 758.2K | 59,744 | — | ↗ |
| 2022-01-19 | Dunn Judith | Officer | A-Award | A | Stock Option (right to buy) | 140,890 | 12.69 | 1.79M | 140,890 | — | ↗ |
| 2022-01-03 | Rajavelu Esther | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 17.82 | 3.56M | 200,000 | — | ↗ |
| 2021-12-31 | Oltmans Curtis Gale | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-08 | Banks Sonja | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 15.73 | 471.9K | 30,000 | — | ↗ |
| 2021-11-10 | Third Rock Ventures III, L.P. | 10% Owner | J-Other | D | Common Stock | 1,000,000 | 0.00 | — | 3,962,202 | — | ↗ |
| 2021-11-10 | LEVIN MARK J | Director / 10% Owner | J-Other | D | Common Stock | 1,000,000 | 0.00 | — | 3,962,202 | — | ↗ |
| 2021-09-22 | Third Rock Ventures III, L.P. | 10% Owner | J-Other | D | Common Stock | 1,000,000 | 0.00 | — | 4,962,202 | — | ↗ |
| 2021-09-22 | LEVIN MARK J | Director / 10% Owner | J-Other | D | Common Stock | 1,000,000 | 0.00 | — | 4,962,202 | — | ↗ |
| 2021-08-11 | Stuart Bryan | Director / Officer | S-Sale | D | Common Stock | 28,000 | 23.75 | 665.0K | 0 | — | ↗ |
| 2021-08-10 | Stuart Bryan | Director / Officer | S-Sale | D | Common Stock | 32,000 | 17.50 | 560.0K | 0 | — | ↗ |
| 2021-08-10 | Moxham Christopher | Officer | S-Sale | D | Common Stock | 20,714 | 17.00 | 352.1K | 0 | — | ↗ |
| 2021-06-28 | Thomson Peter G. | Officer | P-Purchase | A | Common Stock | 2,300 | 9.00 | 20.7K | 2,300 | — | ↗ |
| 2021-06-28 | Oltmans Curtis Gale | Officer | P-Purchase | A | Common Stock | 1,088 | 9.01 | 9.8K | 1,088 | — | ↗ |
| 2021-06-28 | Morabito Christopher | Officer | P-Purchase | A | Common Stock | 1,100 | 9.16 | 10.1K | 1,100 | — | ↗ |
| 2021-06-28 | GERAGHTY JAMES A | Director | P-Purchase | A | Common Stock | 10,000 | 9.16 | 91.6K | 90,714 | — | ↗ |
| 2021-06-09 | LEVIN MARK J | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 8.85 | 132.8K | 15,000 | — | ↗ |
| 2021-06-09 | Haviland Kate | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 8.85 | 132.8K | 15,000 | — | ↗ |
| 2021-06-09 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 8.85 | 132.8K | 15,000 | — | ↗ |
| 2021-06-09 | Ezekowitz Alan | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 8.85 | 132.8K | 15,000 | — | ↗ |
| 2021-06-09 | Dorton Katina | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 8.85 | 132.8K | 15,000 | — | ↗ |
| 2021-06-09 | Collins James J. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 8.85 | 132.8K | 15,000 | — | ↗ |
| 2021-05-10 | Morabito Christopher | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-01 | Dunn Judith | Officer | A-Award | A | Stock Option (right to buy) | 215,000 | 12.00 | 2.58M | 215,000 | — | ↗ |
| 2021-03-31 | Stuart Bryan | Director / Officer | A-Award | A | Stock Option (right to buy) | 350,000 | 11.78 | 4.12M | 350,000 | — | ↗ |
| 2021-03-23 | Dunn Judith | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-16 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 789 | 12.43 | 9.8K | 506,630 | — | ↗ |
| 2021-03-15 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 9,211 | 12.13 | 111.8K | 507,419 | — | ↗ |
| 2021-02-22 | Thomson Peter G. | Officer | M-Exempt | D | Stock Option (right to buy) | 5,000 | 7.84 | 39.2K | 50,471 | — | ↗ |
| 2021-02-16 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 6,542 | 14.19 | 92.8K | 518,303 | — | ↗ |
| 2021-02-08 | Moxham Christopher | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 12.60 | 1.26M | 100,000 | — | ↗ |
| 2021-02-06 | Moxham Christopher | Officer | — | D | Stock Option (right to buy) | 124,286 | 7.84 | 974.4K | 0 | — | ↗ |
| 2021-02-02 | Gould Robert J | Director / Officer | A-Award | A | Stock Option (right to buy) | 269,390 | 11.33 | 3.05M | 269,390 | — | ↗ |
| 2021-01-25 | Thomson Peter G. | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 13.09 | 523.6K | 40,000 | — | ↗ |
| 2021-01-25 | Stuart Bryan | Officer | A-Award | A | Stock Option (right to buy) | 134,376 | 13.09 | 1.76M | 134,376 | — | ↗ |
| 2021-01-21 | Thomson Peter G. | Officer | S-Sale | D | Common Stock | 6,607 | 14.00 | 92.5K | 15,212 | — | ↗ |
| 2021-01-20 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 10,000 | 12.08 | 120.8K | 524,845 | — | ↗ |
| 2020-12-03 | Oltmans Curtis Gale | Officer | A-Award | A | Stock Option (right to buy) | 153,600 | 11.82 | 1.82M | 153,600 | — | ↗ |
| 2020-12-03 | Ezekowitz Alan | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 11.82 | 177.3K | 15,000 | — | ↗ |
| 2020-11-30 | Oltmans Curtis Gale | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-09-14 | Wallace Owen B. | Officer | M-Exempt | A | Common Stock | 6,350 | 7.84 | 49.8K | 133,438 | — | ↗ |
| 2020-07-08 | Wallace Owen B. | Officer | M-Exempt | A | Common Stock | 2,951 | 7.84 | 23.1K | 130,039 | — | ↗ |
| 2020-07-08 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 2,500 | 20.00 | 50.0K | 534,845 | — | ↗ |
| 2020-07-01 | Cadavid Diego | Officer | S-Sale | D | Common Stock | 1,071 | 18.30 | 19.6K | 65,714 | — | ↗ |
| 2020-06-30 | Wallace Owen B. | Officer | M-Exempt | A | Common Stock | 141 | 7.84 | 1.1K | 127,229 | — | ↗ |
| 2020-06-25 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 2,500 | 20.80 | 52.0K | 537,345 | — | ↗ |
| 2020-06-25 | Cadavid Diego | Officer | M-Exempt | A | Common Stock | 1,459 | 4.83 | 7.0K | 68,244 | — | ↗ |
| 2020-06-11 | LEVIN MARK J | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 9,285 | 17.63 | 163.7K | 9,285 | — | ↗ |
| 2020-06-11 | Haviland Kate | Director | A-Award | A | Stock Option (right to buy) | 9,285 | 17.63 | 163.7K | 9,285 | — | ↗ |
| 2020-06-11 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (right to buy) | 9,285 | 17.63 | 163.7K | 9,285 | — | ↗ |
| 2020-06-11 | Ezekowitz Alan | Director | A-Award | A | Stock Option (right to buy) | 9,285 | 17.63 | 163.7K | 9,285 | — | ↗ |
| 2020-06-11 | Collins James J. | Director | A-Award | A | Stock Option (right to buy) | 9,285 | 17.63 | 163.7K | 9,285 | — | ↗ |
| 2020-06-10 | Cadavid Diego | Officer | M-Exempt | D | Stock Option (right to buy) | 401 | 4.83 | 1.9K | 13,736 | — | ↗ |
| 2020-06-09 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 156 | 20.00 | 3.1K | 539,845 | — | ↗ |
| 2020-06-05 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 3,433 | 20.17 | 69.3K | 540,001 | — | ↗ |
| 2020-06-05 | Cadavid Diego | Officer | M-Exempt | A | Common Stock | 451 | 4.83 | 2.2K | 67,236 | — | ↗ |
| 2020-06-04 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 1,300 | 20.04 | 26.1K | 543,434 | — | ↗ |
| 2020-06-04 | Cadavid Diego | Officer | M-Exempt | A | Common Stock | 226 | 4.83 | 1.1K | 67,011 | — | ↗ |
| 2020-06-03 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 1,500 | 20.13 | 30.2K | 544,734 | — | ↗ |
| 2020-06-03 | Cadavid Diego | Officer | M-Exempt | A | Common Stock | 338 | 4.83 | 1.6K | 67,123 | — | ↗ |
| 2020-06-02 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 2,797 | 20.00 | 55.9K | 546,234 | — | ↗ |
| 2020-06-02 | Cadavid Diego | Officer | M-Exempt | A | Common Stock | 45 | 4.83 | 217.35 | 66,830 | — | ↗ |
| 2020-06-01 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 5 | 20.00 | 100.00 | 549,031 | — | ↗ |
| 2020-05-29 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 1,390 | 20.08 | 27.9K | 549,036 | — | ↗ |
| 2020-05-29 | Cadavid Diego | Officer | M-Exempt | A | Common Stock | 200 | 4.83 | 966.00 | 66,985 | — | ↗ |
| 2020-05-28 | Wallace Owen B. | Officer | S-Sale | D | Common Stock | 2,232 | 20.00 | 44.6K | 127,088 | — | ↗ |
| 2020-05-28 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 1,919 | 20.01 | 38.4K | 550,426 | — | ↗ |
| 2020-05-28 | Cadavid Diego | Officer | S-Sale | D | Common Stock | 600 | 20.00 | 12.0K | 66,785 | — | ↗ |
| 2020-05-27 | Wallace Owen B. | Officer | S-Sale | D | Common Stock | 448 | 20.00 | 9.0K | 127,088 | — | ↗ |
| 2020-05-26 | Wallace Owen B. | Officer | M-Exempt | A | Common Stock | 412 | 7.84 | 3.2K | 127,500 | — | ↗ |
| 2020-05-26 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 2,500 | 20.00 | 50.0K | 552,345 | — | ↗ |
| 2020-05-12 | Cadavid Diego | Officer | M-Exempt | D | Stock Option (right to buy) | 1,860 | 4.83 | 9.0K | 15,997 | — | ↗ |
| 2020-05-11 | Thomson Peter G. | Officer | S-Sale | D | Common Stock | 7,500 | 16.00 | 120.0K | 21,071 | — | ↗ |
| 2020-03-02 | Cadavid Diego | Officer | S-Sale | D | Common Stock | 1,828 | 17.26 | 31.5K | 67,100 | — | ↗ |
| 2020-02-24 | Thomson Peter G. | Officer | S-Sale | D | Common Stock | 2,648 | 16.18 | 42.9K | 30,923 | — | ↗ |
| 2020-02-19 | Wallace Owen B. | Officer | M-Exempt | A | Common Stock | 6,088 | 7.84 | 47.7K | 133,176 | — | ↗ |
| 2020-02-19 | Gould Robert J | Director / Officer | S-Sale | D | Common Stock | 2,500 | 20.00 | 50.0K | 554,845 | — | ↗ |
| 2020-02-03 | Cadavid Diego | Officer | S-Sale | D | Common Stock | 2,143 | 17.33 | 37.1K | 68,928 | — | ↗ |
| 2020-01-23 | Wallace Owen B. | Officer | A-Award | A | Stock Option (right to buy) | 58,900 | 16.87 | 993.6K | 58,900 | — | ↗ |
| 2020-01-23 | Thomson Peter G. | Officer | S-Sale | D | Common Stock | 262 | 18.05 | 4.7K | 33,571 | — | ↗ |
| 2020-01-23 | Stuart Bryan | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 16.87 | 1.77M | 105,000 | — | ↗ |
| 2020-01-23 | Gould Robert J | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 16.87 | 3.37M | 200,000 | — | ↗ |
| 2020-01-23 | Cadavid Diego | Officer | A-Award | A | Stock Option (right to buy) | 55,440 | 16.87 | 935.3K | 55,440 | — | ↗ |
| 2020-01-02 | Dorton Katina | Director | A-Award | A | Stock Option (right to buy) | 18,571 | 15.86 | 294.5K | 18,571 | — | ↗ |
| 2019-07-22 | Third Rock Ventures IV, L.P. | 10% Owner | C-Conversion | D | Series A Preferred Stock | 15,833,333 | 0.00 | — | 0 | — | ↗ |
| 2019-07-22 | Third Rock Ventures III, L.P. | 10% Owner | C-Conversion | A | Common Stock | 5,595,238 | 0.00 | — | 5,880,952 | — | ↗ |
| 2019-07-22 | Section 32 Fund 2, LP | 10% Owner | C-Conversion | A | Common Stock | 464,285 | 0.00 | — | 464,285 | — | ↗ |
| 2019-07-22 | Sanofi | 10% Owner | C-Conversion | D | Series B Preferred Stock (par value $0.001) | 3,250,000 | 0.00 | — | 0 | — | ↗ |
| 2019-07-22 | LEVIN MARK J | Director / 10% Owner | C-Conversion | D | Series A Preferred Stock | 39,166,667 | 0.00 | — | 0 | — | ↗ |
| 2019-07-22 | GLAXOSMITHKLINE PLC | 10% Owner | C-Conversion | D | Series B Preferred Stock | 12,500,000 | 0.00 | — | 0 | — | ↗ |
| 2019-07-22 | Casdin Capital, LLC | 10% Owner | C-Conversion | D | Series B Preferred Stock | 3,250,000 | 0.00 | — | 0 | — | ↗ |
| 2019-07-22 | 6 Dimensions Capital, L.P. | 10% Owner | C-Conversion | A | Common Stock | 441,071 | 0.00 | — | 441,071 | — | ↗ |
| 2019-07-18 | Wallace Owen B. | Officer | A-Award | A | Stock Option (right to buy) | 44,493 | 16.00 | 711.9K | 44,493 | — | ↗ |
| 2019-07-18 | Thomson Peter G. | Officer | A-Award | A | Stock Option (right to buy) | 7,078 | 16.00 | 113.2K | 7,078 | — | ↗ |
| 2019-07-18 | Stuart Bryan | Officer | A-Award | A | Stock Option (right to buy) | 28,571 | 16.00 | 457.1K | 28,571 | — | ↗ |
| 2019-07-18 | Haviland Kate | Director | A-Award | A | Stock Option (right to buy) | 9,285 | 16.00 | 148.6K | 9,285 | — | ↗ |
| 2019-07-18 | Gould Robert J | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 107,142 | 16.00 | 1.71M | 107,142 | — | ↗ |
| 2019-07-18 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (right to buy) | 9,285 | 16.00 | 148.6K | 9,285 | — | ↗ |
| 2019-07-18 | Ezekowitz Alan | Director | A-Award | A | Stock Option (right to buy) | 5,714 | 16.00 | 91.4K | 5,714 | — | ↗ |
| 2019-07-18 | Collins James J. | Director | A-Award | A | Stock Option (right to buy) | 5,714 | 16.00 | 91.4K | 5,714 | — | ↗ |
| 2019-07-18 | Cadavid Diego | Officer | A-Award | A | Stock Option (right to buy) | 12,784 | 16.00 | 204.5K | 12,784 | — | ↗ |
| 2019-07-17 | Wallace Owen B. | Officer | — | D | Common Stock | 0 | 0.00 | — | 127,088 | — | ↗ |
| 2019-07-17 | Thomson Peter G. | Officer | — | D | Stock Option (right to buy) | 55,471 | 7.84 | 434.9K | 0 | — | ↗ |
| 2019-07-17 | Third Rock Ventures IV, L.P. | 10% Owner | — | I | Series A Preferred Stock | 2,261,904 | 0.00 | — | 0 | — | ↗ |
| 2019-07-17 | Third Rock Ventures III, L.P. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 285,714 | — | ↗ |
| 2019-07-17 | Stuart Bryan | Officer | — | D | Stock Option (right to buy) | 58,928 | 7.84 | 462.0K | 0 | — | ↗ |
| 2019-07-17 | Section 32 Fund 2, LP | 10% Owner | — | D | Series B Preferred Stock | 464,285 | 0.00 | — | 0 | — | ↗ |
| 2019-07-17 | Sanofi | 10% Owner | — | I | Series B Preferred Stock (par value, $0.001) | 464,285 | 0.00 | — | 0 | — | ↗ |
| 2019-07-17 | LEVIN MARK J | Director / 10% Owner | — | I | Series A Preferred Stock | 5,595,238 | 0.00 | — | 0 | — | ↗ |
| 2019-07-17 | Haviland Kate | Director | — | D | Stock Option (right to buy) | 23,571 | 4.83 | 113.8K | 0 | — | ↗ |
| 2019-07-17 | Gould Robert J | Director / Officer / 10% Owner | — | D | Stock Option (right to buy) | 324,462 | 7.84 | 2.54M | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
54.11M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Alex C. Sapir President and Chief Executive Officer | 650.0K | — | — | 2.05M | 411.2K | 138.2K | 3.25M | 63.11% | ↗ |
| 2 | 2025 | Alan Musso Chief Financial Officer | 478.1K | — | — | 1.00M | 220.0K | 104.1K | 1.81M | 55.61% | ↗ |
| 3 | 2025 | Curtis Oltmans Chief Legal Officer and Head of External Affairs | 472.2K | — | — | 793.4K | 217.3K | — | 1.48M | 53.50% | ↗ |
| 4 | 2024 | Patrick Horn Former Chief Medical Officer | 395.8K | — | — | 3.33M | — | — | 3.73M | 89.39% | ↗ |
| 5 | 2024 | Curtis Oltmans Chief Legal Officer and Head of External Affairs | 454.0K | — | — | 853.1K | 118.1K | — | 1.43M | 59.86% | ↗ |
| 6 | 2024 | Curtis Oltmans Chief Legal Officer | 454.0K | — | — | 853.1K | 118.1K | — | 1.43M | 59.86% | ↗ |
| 7 | 2024 | Alan Musso Chief Financial Officer | 457.5K | — | — | 568.8K | 119.0K | 106.5K | 1.25M | 45.44% | ↗ |
| 8 | 2024 | Alex C. Sapir President and Chief Executive Officer | 650.0K | — | — | — | 211.3K | 142.0K | 1.00M | 0.00% | ↗ |
| 9 | 2023 | Alex C. Sapir President and Chief Executive Officer | 369.4K | — | — | 6.40M | 150.0K | 72.4K | 6.99M | 91.53% | ↗ |
| 10 | 2023 | Curtis Oltmans Chief Legal Officer | 436.8K | — | — | 1.73M | 148.6K | — | 2.32M | 74.76% | ↗ |
| 11 | 2023 | Mel Hayes Executive Vice President, Patient Affairs | 471.2K | — | — | 1.56M | 160.3K | — | 2.19M | 71.20% | ↗ |
| 12 | 2023 | Alan Musso Chief Financial Officer | 180.7K | — | — | 1.61M | 61.7K | 31.7K | 1.88M | 85.42% | ↗ |
| 13 | 2023 | Bryan Stuart Former President and Chief Executive Officer | 2.4K | — | — | 1.29M | — | 572.5K | 1.87M | 69.26% | ↗ |
| 14 | 2023 | Robert J. Gould Former Interim President and Chief Executive Officer | 300.0K | — | — | 76.4K | — | 48.1K | 424.5K | 18.00% | ↗ |
| 15 | 2022 | Bryan Stuart Former President and Chief Executive Officer | 572.5K | — | — | 3.18M | 220.0K | — | 3.97M | 80.05% | ↗ |
| 16 | 2022 | Esther Rajavelu Former Chief Financial Officer | 435.0K | 150.0K | — | 2.64M | 121.2K | — | 3.35M | 78.92% | ↗ |
| 17 | 2022 | Santiago Arroyo Former Chief Medical Officer | 75.8K | — | — | 1.77M | 30.2K | — | 1.88M | 94.35% | ↗ |
| 18 | 2022 | Curtis Oltmans Chief Legal Officer | 411.8K | — | — | 840.9K | 117.6K | — | 1.37M | 61.37% | ↗ |
| 19 | 2022 | Robert J. Gould Former Interim President and Chief Executive Officer | — | — | — | 73.3K | — | 45.0K | 118.3K | 61.97% | ↗ |
| 20 | 2021 | Bryan Stuart Former President and Chief Executive Officer | 515.4K | — | — | 4.22M | 321.0K | — | 5.06M | 83.45% | ↗ |
| 21 | 2021 | Bryan Stuart President and Chief Executive Officer | 515.4K | — | — | 4.22M | 321.0K | — | 5.06M | 83.45% | ↗ |
| 22 | 2021 | Judith Dunn President, Research and Development | 337.5K | — | — | 1.88M | 216.0K | — | 2.43M | 77.22% | ↗ |
| 23 | 2021 | Robert J. Gould Former President and Chief Executive Officer | 167.7K | — | — | 2.17M | — | — | 2.34M | 92.84% | ↗ |
| 24 | 2021 | Christopher Morabito Chief Medical Officer | 274.5K | — | — | 1.19M | 204.0K | — | 1.66M | 71.25% | ↗ |
| 25 | 2020 | Robert J. Gould President and Chief Executive Officer | 535.0K | 240.8K | — | 2.24M | — | — | 3.02M | 74.28% | ↗ |
| 26 | 2020 | Robert J. Gould Former President and Chief Executive Officer | 535.0K | — | — | 2.24M | 240.8K | — | 3.02M | 74.28% | ↗ |
| 27 | 2020 | Bryan Stuart President and Chief Executive Officer | 440.0K | — | — | 1.18M | 158.4K | — | 1.77M | 66.28% | ↗ |
| 28 | 2020 | Bryan Stuart Chief Operating Officer | 440.0K | 158.4K | — | 1.18M | — | — | 1.77M | 66.28% | ↗ |
| 29 | 2020 | Curtis Oltmans General Counsel | 34.0K | 50.0K | — | 1.27M | — | — | 1.36M | 93.81% | ↗ |
| 30 | 2019 | Robert J. Gould President and Chief Executive Officer | 478.2K | 300.0K | — | 3.11M | — | — | 3.89M | 79.99% | ↗ |
| 31 | 2019 | Owen Wallace Chief Scientific Officer | 381.5K | 126.0K | — | 1.05M | — | — | 1.56M | 67.46% | ↗ |
| 32 | 2019 | Bryan Stuart Chief Operating Officer | 406.8K | 183.0K | — | 645.1K | — | — | 1.23M | 52.24% | ↗ |
| 33 | 2018 | Bryan Stuart Chief Operating Officer | 16.7K | — | — | 1.69M | — | — | 1.70M | 99.02% | ↗ |
| 34 | 2018 | Robert J. Gould President and Chief Executive Officer | 442.9K | 203.7K | 207.0K | — | — | — | 853.6K | 24.25% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alexander C. Sapir | Chief Executive Officer, President & Director | 1M | male |
| Alan A. Musso | Chief Financial Officer | 802.2K | male |
| Curtis G. Oltmans | Chief Legal Officer, Head of External Affairs & Corporate Secretary | 689.5K | male |
| Gregory Tourangeau | Controller & Principal Accounting Officer | — | male |
| Jeffrey W. Jacobs | Chief Scientific Officer | — | — |
| Kim Hazen | Chief People Officer | — | female |
| Michael R. Green | Founder | — | — |
| Rudolf Jaenisch | Founder | — | — |
| Tsun-Huei Lee | Founder | — | — |
| Bradley E. Bernstein | Founder | — | — |
| Danny Reinberg | Founder | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FULC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
